, /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: ) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company posted a new Shareholder Update Letter on its website and further invites interested parties to subscribe to their email alert service to stay up to date on company's progress here: . (Note: not all updates will be included in a Press Release in the future).
Today's update highlights potential paths to profitability for NRx in 2025. Key items include: Please subscribe to the Company's email for future updates. Not all of these will be the subject of a Press Release in the future.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression.
NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine), in the treatment of suicidal depression, based on results of well-controlled clinica.